|Elimination half-life||14–18 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||365.835 g/mol g·mol−1|
|3D model (JSmol)|
Indapamide is a thiazide-like diuretic drug generally used in the treatment of hypertension, as well as decompensated heart failure. Combination preparations with perindopril (an ACE inhibitor antihypertensive) are also available. The thiazide-like diuretics (indapamide and chlorthalidone) are more effective than the thiazide-type diuretics (including hydrochlorothiazide) for reducing the risk of heart attack, stroke, and heart failure in persons with high blood pressure and the thiazide-like and thiazide-type diuretics have similar rates of adverse effects.
It was patented in 1968 and approved for medical use in 1977.
Hypertension and edema due to congestive heart failure. Indapamide has been proven in the HYVET trial to reduce stroke and all-cause mortality when given with or without perindopril to people over the age of 80 for the treatment of hypertension.[non-primary source needed]
Caution is advised in the combination of indapamide with lithium and nonantiarrhythmic drugs causing wave-burst arrhythmia (astemizole, bepridil, IV erythromycin, halofantrine, pentamidine, sultopride, terfenadine, and vincamine).
Symptoms of overdosage would be those associated with a diuretic effect, i.e. electrolyte disturbances, low blood pressure, and muscular weakness. Treatment should be symptomatic, directed at correcting electrolyte abnormalities.
Dosage and administration
The adult dosage is 1.25 to 5 mg, orally and once daily, usually in the morning.
Indapamide is available generically as 1.25 mg and 2.5 mg non-scored tablets. It is also available in SR (sustained release) form.
- Indapamide at the US National Library of Medicine Medical Subject Headings (MeSH)
- Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ (May 2015). "Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis". Hypertension. 65 (5): 1033–40. doi:10.1161/HYPERTENSIONAHA.114.05122. PMID 25733241.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 457. ISBN 9783527607495.
- Beckett, NS; Peters, R; Fletcher, AE; et al. (May 2008). "HYVET Trial". N. Engl. J. Med. 358 (18): 1887–98. doi:10.1056/NEJMoa0801369. PMID 18378519.
- "Lexicomp Online Login". lexi.com.